These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 12595437)
1. Activation of natural killer T cells by alpha-galactosylceramide impairs DNA vaccine-induced protective immunity against Trypanosoma cruzi. Miyahira Y; Katae M; Takeda K; Yagita H; Okumura K; Kobayashi S; Takeuchi T; Kamiyama T; Fukuchi Y; Aoki T Infect Immun; 2003 Mar; 71(3):1234-41. PubMed ID: 12595437 [TBL] [Abstract][Full Text] [Related]
2. During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein. Duthie MS; Wleklinski-Lee M; Smith S; Nakayama T; Taniguchi M; Kahn SJ Infect Immun; 2002 Jan; 70(1):36-48. PubMed ID: 11748161 [TBL] [Abstract][Full Text] [Related]
3. During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment. Duthie MS; Kahn SJ Immunology; 2006 Nov; 119(3):355-61. PubMed ID: 16879622 [TBL] [Abstract][Full Text] [Related]
4. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells. Limon-Flores AY; Cervera-Cetina R; Tzec-Arjona JL; Ek-Macias L; Sánchez-Burgos G; Ramirez-Sierra MJ; Cruz-Chan JV; VanWynsberghe NR; Dumonteil E Vaccine; 2010 Oct; 28(46):7414-9. PubMed ID: 20850536 [TBL] [Abstract][Full Text] [Related]
8. Genetic immunization based on the ubiquitin-fusion degradation pathway against Trypanosoma cruzi. Chou B; Hiromatsu K; Hisaeda H; Duan X; Imai T; Murata S; Tanaka K; Himeno K Biochem Biophys Res Commun; 2010 Feb; 392(3):277-82. PubMed ID: 20059980 [TBL] [Abstract][Full Text] [Related]
9. DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Fujimura AE; Kinoshita SS; Pereira-Chioccola VL; Rodrigues MM Infect Immun; 2001 Sep; 69(9):5477-86. PubMed ID: 11500420 [TBL] [Abstract][Full Text] [Related]
10. Critical contribution of CD28-CD80/CD86 costimulatory pathway to protection from Trypanosoma cruzi infection. Miyahira Y; Katae M; Kobayashi S; Takeuchi T; Fukuchi Y; Abe R; Okumura K; Yagita H; Aoki T Infect Immun; 2003 Jun; 71(6):3131-7. PubMed ID: 12761091 [TBL] [Abstract][Full Text] [Related]
11. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Barry MA; Wang Q; Jones KM; Heffernan MJ; Buhaya MH; Beaumier CM; Keegan BP; Zhan B; Dumonteil E; Bottazzi ME; Hotez PJ Hum Vaccin Immunother; 2016 Apr; 12(4):976-87. PubMed ID: 26890466 [TBL] [Abstract][Full Text] [Related]
12. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Katae M; Miyahira Y; Takeda K; Matsuda H; Yagita H; Okumura K; Takeuchi T; Kamiyama T; Ohwada A; Fukuchi Y; Aoki T Infect Immun; 2002 Sep; 70(9):4833-40. PubMed ID: 12183527 [TBL] [Abstract][Full Text] [Related]
13. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768 [TBL] [Abstract][Full Text] [Related]
14. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction? Basso B; Marini V Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810 [TBL] [Abstract][Full Text] [Related]
15. Experimental Nanovaccine Offers Protection Against Repeat Exposures to Chowdhury IH; Lokugamage N; Garg NJ Front Immunol; 2020; 11():595039. PubMed ID: 33414785 [TBL] [Abstract][Full Text] [Related]
16. Trypanosoma cruzi: protective response of vaccinated mice is mediated by CD8+ cells, prevents signs of polyclonal T lymphocyte activation, and allows restoration of a resting immune state after challenge. Paiva CN; Castelo-Branco MT; Lannes-Vieira J; Gattass CR Exp Parasitol; 1999 Jan; 91(1):7-19. PubMed ID: 9920038 [TBL] [Abstract][Full Text] [Related]
17. Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein. Chou B; Hisaeda H; Shen J; Duan X; Imai T; Tu L; Murata S; Tanaka K; Himeno K Microbes Infect; 2008 Mar; 10(3):241-50. PubMed ID: 18321749 [TBL] [Abstract][Full Text] [Related]
18. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway. Procópio DO; Almeida IC; Torrecilhas AC; Cardoso JE; Teyton L; Travassos LR; Bendelac A; Gazzinelli RT J Immunol; 2002 Oct; 169(7):3926-33. PubMed ID: 12244192 [TBL] [Abstract][Full Text] [Related]
19. Treatment with alpha-galactosylceramide before Trypanosoma cruzi infection provides protection or induces failure to thrive. Duthie MS; Kahn SJ J Immunol; 2002 Jun; 168(11):5778-85. PubMed ID: 12023379 [TBL] [Abstract][Full Text] [Related]